- Home
- HKD vs RCKT Comparison
HKD vs RCKT Comparison
Compare HKD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HKD | RCKT |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | France | United States |
| Employees | N/A | 202 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.3M | 503.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HKD | RCKT |
|---|---|---|
| Price | $1.56 | $4.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.65 |
| AVG Volume (30 Days) | 681.5K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $2.19 |
| 52 Week High | $5.47 | $8.91 |
Technical Indicators
Market Signals| Indicator | HKD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 60.56 |
| Support Level | $1.32 | $2.99 |
| Resistance Level | $1.68 | $4.51 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 22.30 | 57.31 |
Price Performance
Historical ComparisonAbout HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.